Skip to Content

Correlation between incidence of immune-related adverse events on atezolizumab and survival outcome

An exploratory pooled analysis based on three phase III studies on NSCLC suggests that immune-related adverse events to atezolizumab may indicate that the treatment is effective in that particular patient.

Doctor looking at lung patient's x-ray

Lue artikkeli

Jos olet lääkäri, farmaseutti tai rajatun lääkkeenmääräämisoikeuden omaava sairaanhoitaja, pääset lukemaan artikkelin kirjautumalla käyttäjäksi BestPractice Nordic -sivustolle.

Back to top